Other languages Annexon, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 16:55:46 02/05/2024 BST			5-day change	1st Jan Change
4.675 ^USD	-1.58%		+0.65%	+1.76%

04-01	JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating	MT
03-27	Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating	MT

Annexon Q4 Loss Narrows	03-26
Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Annexon, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26
Annexon Insider Bought Shares Worth $1,008,000, According to a Recent SEC Filing	12-28
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	12-21
Sector Update: Health Care Stocks Advance in Afternoon Trading	12-21
Sector Update: Health Care	12-21
Annexon Shares Jump on Stock Offering Pricing, BofA Upgrade	12-21
Annexon Prices $125 Million Share Offering	12-21
Annexon, Inc. Outlines Global Registrational Program for Anx007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint	12-20
Annexon Reports Phase 1 Results for ANX1502, Its Oral Small Molecule Inhibitor of the Classical Complement Pathway	12-20
Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Annexon Q2 Loss Narrows	07/08/23
Annexon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23
Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer	31/07/23
Annexon's Ongoing Trial of ANX007 Shows Dose-Dependent Protection From Vision Loss	31/07/23
Top Midday Decliners	25/05/23
Sector Update: Health Care Stocks Slip Pre-Bell Thursday	25/05/23
Top Premarket Decliners	25/05/23
Annexon Reports Results From Phase 2 Trial of Geographic Atrophy; Shares Plunge Premarket	25/05/23

No results for this search